Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR antibodies), ...

Treatment with inebilizumab was associated with continued improvement in patients with acetylcholine receptor autoantibody-positive (AChR+) generalized myasthenia gravis (gMG), according to 52-week ...

for pediatric patients aged six years and older with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. This landmark approval makes Soliris the ...

in adults with the rare autoimmune disorder generalised myasthenia gravis (gMG). The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody (MuSK) ...

adult gMG with AChR antibodies and neuromyelitis optica spectrum disorder. “This approval represents a major advancement in the treatment of pediatric myasthenia gravis and provides hope to ...

The FDA approves Amgen's Uplizna as the first and only drug for the treatment of immunoglobulin G4-related disease.

“This approval represents a major advancement in the treatment of pediatric myasthenia gravis and provides hope ... syndrome (2011), adult gMG with AChR antibodies (2017), and neuromyelitis ...

Approval in Myasthenia gravis in key markets could eventually ... open-label study which found benefits for patients with anti-AchR antibody-positive gMG who had previously failed ...

Like Soliris and Ultomiris, Zilbrysq is approved for use in adults with gMG who are anti-acetylcholine receptor (AChR) antibody ... chief executive of the Myasthenia Gravis Foundation of America.

Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today revealed that ...